Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2009. The document serves as a notification of a transaction involving a director or person discharging managerial responsibility, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to a specific share transaction notification.
Material Changes
On May 19, 2009, Mr. D S Redfern purchased 3,250 Ordinary shares of GlaxoSmithKline plc at a price of £10.54 per share. This transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific share purchase notification.
Investor Verification Points
- Verify the total shareholding of Mr. D S Redfern following the purchase of 3,250 shares.
- Confirm the market price of GSK Ordinary shares on May 19, 2009, relative to the transaction price of £10.54.
- Check subsequent filings for any further changes in interests by directors or connected persons.